MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...

Obstructive hypertrophic cardiomyopathy symptoms such as trouble breathing, a racing heart, and fatigue can make daily tasks ...

Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Novel mavacamten ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

"Women come significantly later to their cardiologists and have the same peri-procedural [alcohol septal ablation] complications and worse long-term outcomes, which are caused by their older age; ...

Hypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Obstructive hypertrophic cardiomyopathy comes with symptoms such as shortness of breath, fatigue, and palpitations. These tips can help you manage it.

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...